Aurinia Pharmaceuticals (AUPH) Downgraded by Zacks Investment Research to Sell

Aurinia Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Aurinia Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Aurinia Pharmaceuticals traded up $1.15 on Monday, reaching $20.48. 4871227 shares of the stock traded hands, compared to its average volume of 4067928. Shares of Aurinia Pharmaceuticals were trading at $20.48 on Monday. The firm’s 50 day moving average is $18.06 and its 200 day moving average is $14.58.Aurinia Pharmaceuticals has a 12 month low of $18.33 and a 12 month high of $24.18. While on yearly highs and lows, Aurinia Pharmaceuticals’s today has traded high as $20.98 and has touched $18.33 on the downward trend. See More Analyst Rating at: RATING

Aurinia Pharmaceuticals Earnings and What to expect: 

Aurinia Pharmaceuticals last announced its earnings data on August 4th, 2021. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.02. The firm had revenue of $6.62 million for the quarter, compared to the consensus estimate of $4.98 million. Aurinia Pharmaceuticals has generated ($0.87) earnings per share over the last year (($1.10) diluted earnings per share). Earnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($1.34) to ($0.43) per share. Aurinia Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($1.34) to ($0.43) per share. The P/E ratio of Aurinia Pharmaceuticals is -18.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Aurinia Pharmaceuticals is -18.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Aurinia Pharmaceuticals has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Aurinia Pharmaceuticals (AUPH) Moving Average Technical Analysis

5 day Moving Average is $19.96 And 5 day price change is -$0.61 (-2.89%)  with average volume for 5 day average is 3,864,260. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $21.50 and 20 day price change is -$0.45 (-2.15%) and average 20 day moving volume is 4,205,570. 50 day moving average is $18.06  and 50 day price change is $6.92 ( 51.03%)  and with average volume for 50 days is : 4,215,492. 200 day moving average is $14.58  and 200 day price change is $7.04 (52.38%)  and with average volume for 200 days is : 4,082,021.

Other owners latest trading in Aurinia Pharmaceuticals :

  • On 9/17/2021 shares held by Virtu Financial LLC were 67,123 which equates to market value of $0.87M and appx 0.10% owners of Aurinia Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 32,796 which equates to market value of $0.43M and appx 0.00% owners of Aurinia Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 3,621,692 which equates to market value of $46.94M and appx 0.00% owners of Aurinia Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 38.27% for Aurinia Pharmaceuticals

See More Analyst Rating at: RATING